Molecular profiling of renal cell carcinoma presenting as iris metastasis

Osorio Lopes Abath Neto a, Zachary A. Koretz b, Abigail I. Wald a, Pamela P. Rath c, Marina Nikiforova a, Charleen T. Chu a,∗

a Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
b Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
c Everett & Hurite Ophthalmic Association, Pittsburgh, PA, USA

ABSTRACT

Keywords:
Iris metastasis
Clear cell renal cell carcinoma
TERT
iris Lesion
Tumor molecular genetics

Purpose: To describe a case of iris metastasis as the initial presentation of clear cell renal cell carcinoma, and to discuss molecular profiling of both the metastasis and primary kidney tumor.

Observations: We report a patient with blurred vision who underwent ophthalmic examination and was found to have an iris mass, which was excised and diagnosed as a metastatic clear cell renal cell carcinoma by morphology and immunohistochemical analysis. As a result of the pathology findings, computed tomography imaging was performed, revealing a right kidney mass, which was also resected and shown to represent a high-grade carcinoma confined within the renal fascia without lymphovascular invasion. Molecular testing of the primary and metastatic tumors using a custom next-generation sequencing panel revealed similar mutational profiles but disclosed a TERT promoter mutation in the primary neoplasm, not present in the metastasis, suggesting seeding of an early lower grade neoplastic cell clone within the iris.

Conclusions and importance: This report illustrates how pathological examination of a small iris lesion led to the discovery of a previously unknown systemic malignancy at a resectable stage. Molecular genetic profiling revealed that even lower grade clones within a high-grade neoplasm have metastatic potential.

1. Introduction

The iris is a rare location for metastatic spread of cancer, particularly without a known primary neoplasm. Iris metastases most frequently originate from the breast and lung and occur in the setting of preexistent metastatic disease to other organs.1 Renal cell carcinomas may metastasize to virtually any organ,2 but there are only very rare reports of iris metastases, typically involving widely disseminated disease.3 Molecular studies to better understand the profile of metastatic renal cell carcinomas to the iris are lacking. We report a case of clear cell renal cell carcinoma (ccRCC) presenting as an incidental iris lesion during the workup for cataract and show that the metastasis likely originated from a lower grade clone within the high-grade primary tumor.

2. Case report

A 56-year-old man with hypertension and a 40-pack-year smoking history presented for evaluation of 3 months of painless blurred vision in the right eye. An iris lesion, not present 2 years earlier, was noted. Visual acuity was 20/70 on the right, improving to 20/40 with pinhole, and 20/20 on the left, with normal intraocular pressures. Slit-lamp examination (Fig. 1) revealed rare, pigmented cells in the right anterior chamber, 20/20 on the left, with normal intraocular pressures. Slit-lamp examination (Fig. 1) revealed rare, pigmented cells in the right anterior chamber, posterior synechiae (nearly 360°), focal iris elevation and iridocorneal apposition at 5:00. There was nuclear sclerosis and pigment on the anterior lens capsule. Gonioscopy demonstrated focal angle closure at 5:00. Left slit-lamp and bilateral fundoscopic examinations were unremarkable. Ultrasound biomicroscopy (Fig. 1) showed a circumscribed 2.2 mm × 3.5 mm heterogeneously hyperechoic mass within the right iris associated with synechiae and mass effect on the crystalline lens. The patient was primarily concerned with visual improvement. Therefore, an excisional iris wedge resection, synechiotomy, pupilloplasty and cataract extraction with intraocular lens implantation were performed simultaneously for definitive diagnosis and vision restoration. Two months later, visual acuity improved to 20/20. Histopathology revealed expansion of the iris stroma by nests of clear cells in a vascular background (Fig. 2). As the tissue was received in several small pieces, it was not possible to fully assess the surgical margins. Neoplastic cells were immunoreactive for pancytokeratins...

https://doi.org/10.1016/j.ajoc.2022.101599
Received 1 February 2022; Received in revised form 19 May 2022; Accepted 22 May 2022
Available online 24 May 2022
2451-9936/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3. Discussion

This case exemplifies an unusual presentation of a previously unsuspected high-grade primary ccRCC following incidental discovery of an iris metastasis showing low-grade histology. Clear cell renal cell carcinoma (ccRCC) is the most common primary renal tumor, corresponding to more than 80% of cases. While up to half of ccRCCs are confined to the kidney at presentation, approximately 30% develop metastases.4

Although the iris metastasis was the only evidence of dissemination after extensive systemic workup, there were multiple histologic markers of poor prognosis in the primary neoplasm. Sarcomatoid or rhabdoid differentiation, defining features of the highest WHO/ISUP grade, independently confer 5-year survival rates of 15–20%. Necrosis (≥10%) also correlates with unfavorable outcomes.5

The molecular profiles of the primary and metastasis shared common mutations for ccRCC in VHL and SETD2. The VHL tumor suppressor gene, located in chromosome 3p, is mutated in the large majority of sporadic ccRCCs and all that occur in the familial von Hippel-Lindau setting. SETD2, which encodes a histone-3-lysine-methyltransferase, also in 3p, is mutated in 13% of ccRCCs.

Interestingly, the primary tumor exhibited the TERT promoter C228T mutation, which is associated with aggressive behavior in ccRCC,
glioblastomas, urothelial and thyroid carcinomas. The TERT C228T may have been a late acquisition of the primary tumor after metastatic seeding, or the cell clone from which the iris metastasis derived may have originated in a heterogeneous tumor region lacking the mutation. In any event, the absence of TERT abnormality in the metastasis supports the notion that an aberrant VHL protein is sufficient to confer metastatic capacity in ccRCCs, as previously proposed in tumors with low grade histology.

4. Conclusions

In this case, pathology from the excision of an iris lesion led to the detection of an asymptomatic high-grade renal cell carcinoma at a stage where the mass was still resectable, and not widely disseminated. Additionally, the histologic and molecular features of the iris metastasis are in keeping with a low-grade clone of the kidney primary, which could suggest a better prognosis for the patient considering that both tumors were resected and show no histological evidence of lymphovascular invasion.

Patient consent

The patient gave written informed consent to publish the case (including publication of images).

Acknowledgments and Disclosures

The authors have no conflicts of interest or financial disclosures. The authors alone are responsible for the content and writing of this article. All authors attest that they meet the current ICMJE criteria for Authorship. The authors thank Dr. Raja Seethala and Dr. Sheldon Bastacky for surgical pathology consultation.

References

1. Shields CL, Kaliki S, Crabtree GS, et al. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea. 2015;34(1):42–48.
2. Weiss L, Harlos JP, Torhorsl J, et al. Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol. 1988;114:605–612.
3. Ware GT, Halk BG, Morris WR. Renal cell carcinoma with involvement of iris and conjunctiva. Am J Ophthalmol. 1999;127(4):460–461.
4. Moch H, Humphrey PA, Ulbright TM, Reuter V. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016.
5. Hosen I, Rachakonda PS, Heidenreich B, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer. 2015;136(10):2448–2452.
6. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425:307–311.